Navigation Links
Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications

MADISON, N.J., Sept. 3 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) today announced the appointment of Daniel J. McIntyre, 54, to Vice President, Corporate Communications. Reporting to Timothy P. Cost, Senior Vice President, Corporate Affairs, Mr. McIntyre will be responsible for all internal and external communications for the corporation and its three major divisions -- pharmaceuticals, consumer health care and animal health -- around the world.

Prior to joining Wyeth, Mr. McIntyre held a series of senior executive positions in communications and health care. Most recently, he was Managing Director of the healthcare practice of Fleishman-Hillard International Communications. He previously served in senior level Communications and Public Policy positions for Pharmacia Corporation, Bayer Corporation's Pharmaceutical Division, the Bristol-Myers Squibb Company, and Hoffmann-La Roche Inc.

"Wyeth is in one of the most important periods in its history," says Mr. Cost. "We are building momentum toward developing new therapies for patients even as we transform our organization for the future. Having Dan now leading our communications team is an important part of our plan to meet new and evolving challenges."

An honors graduate of Seton Hall University, McIntyre holds an MPA from Rutgers University. He is a member of the executive committee of the Rutgers University Foundation, and has served on the boards of trustees of Caldwell College, the American Association for World Health, the New England Healthcare Institute (NEHI) and Connecticut United for Research Excellence (CURE). He is also a member of the Public Relations Society of America (PRSA).

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit
2. Wyeths Motion to Overturn Punitive Damages Award Granted by Arkansas Court
3. Wyeth Announces Bernard Poussot Assumes Chairman of the Board Position
4. Wyeth Declares Common and Preferred Stock Dividends
5. Wyeth Pharmaceuticals Announces Organizational Change
6. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
7. Wyeth to Present at the 2008 Citi Investment Research Global Healthcare Conference
8. Wyeth Research Head Robert R. Ruffolo, Jr., Ph.D., Announces Retirement
9. Wyeth Chairman Robert Essner Announces June 27 Retirement
10. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
11. Wyeth to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
Post Your Comments:
(Date:6/27/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... major shareholders, Clean Technology Fund I, LP and Clean ... based venture capital funds which together hold approximately ... fully diluted, as converted basis), that they have entered ... equity holdings in Biorem to TUS Holdings Co. Ltd. ...
(Date:6/27/2016)... ... ... Parallel 6 , the leading software as a service (SaaS) provider ... Patient Encounter CONSULT module which enables both audio and video telemedicine communication between the ... the CONSULT module, patients and physicians can schedule a face to face virtual patient ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
Breaking Biology Technology:
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of ... the latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Medical Display- Ampronix News ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: ... banks to provide their customers enhanced security to ...
Breaking Biology News(10 mins):